caa a22 4500 475802004 CHVBK 20180406123740.0 cr unu---uuuuu 170329e20000701xx s 000 0 eng 10.1007/s002680010125 doi (NATIONALLICENCE)springer-10.1007/s002680010125 Schwartz Robert S. 10 Shattuck Street, Boston, Massachusetts 02115, USA, US aut Immunosuppression—Back to the Future [Elektronische Daten] [Robert S. Schwartz] Abstract.: During the 1950s work on bone marrow transplantation for patients with aplastic anemia led to the search for means other than total body irradiation to prevent rejection of the bone marrow allograft. At the same time, it had become clear that lymphocyte proliferation was a prominent feature of the immune response against all kinds of antigens, including skin allografts. These two factors led us to test various chemical agents known to block the proliferation of leukemic lymphocytes for their ability to inhibit the immune response against soluble antigens and skin allografts. One compound, the antileukemic drug 6-mercaptopurine, was effective in both test systems. This drug and its sister compound azathioprine (which is mercaptopurine with an imidizaole ring instead of a sulfhydryl group on carbon 6) were soon applied to human allografting and the treatment of autoimmune diseases. by Société Internionale de Chirurgie, 2000 World Journal of Surgery Springer-Verlag 24/7(2000-07-01), 783-786 0364-2313 24:7<783 2000 24 268 https://doi.org/10.1007/s002680010125 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s002680010125 text/html Onlinezugriff via DOI NATIONALLICENCE 100 1- Schwartz Robert S. 10 Shattuck Street, Boston, Massachusetts 02115, USA, US aut NATIONALLICENCE 773 0- World Journal of Surgery Springer-Verlag 24/7(2000-07-01), 783-786 0364-2313 24:7<783 2000 24 268 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer